HHS Eyed Optimal Use Of Protease Inhibitors Even Before Victrelis Approval
Executive Summary
Even before FDA’s May 13 approval of Merck’s protease inhibitor Victrelis (boceprevir) for hepatitis C, federal health officials were eyeing the best way to maximize treatment with this new class of drugs.
You may also be interested in...
Protease Inhibitors Could Get Hepatitis C Market Boost From CDC Funding Request
A series of federal public health initiatives are aligning to expand the market for the first two protease inhibitors expected to win approval for hepatitis C treatment.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.